{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-095892","form_type":"8-K/A","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2026-08-13T20:05:24+00:00","discovered_at":"2026-08-13T20:07:00.108272+00:00","generated_at":"2026-08-13T20:07:06.274295+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TELA Bio CEO Koblish separation agreement: 12-month salary, equity acceleration","bullets":["Separation Agreement executed Aug 7, 2026; CEO departure effective Aug 3, 2026.","Severance: 12 months base salary paid ratably over 12 months; COBRA premiums paid for 12 months.","All equity awards accelerate and fully vest; option exercise period extended to Dec 31, 2027.","Performance stock units remain eligible to vest on 2026 revenue/gross margin goals; vest at target on change in control.","Includes general release and waiver of claims against TELA Bio."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-095892","json":"https://secwatch.observer/filing/0001104659-26-095892.json","markdown":"https://secwatch.observer/filing/0001104659-26-095892.md","text":"https://secwatch.observer/filing/0001104659-26-095892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926095892/0001104659-26-095892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926095892/tm2622979d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:07:06.274295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}